Plaque regression associated with everolimus administration after heart transplantation

详细信息    查看全文

• 作者：Daisaku Nakatani ; MD^a ; ^{nakatani@cardiology.med.osaka-u.ac.jp} ; Jun-ichi Kotani ; MD^b ; Koichi Tachibana ; MD^a ; Yasuhiro Ichibori ; MD^a ; Isamu Mizote ; MD^a ; Yoshihiro Asano ; MD^a ; Yasushi Sakata ; MD^a ; Yasuhiko Sakata ; MD^a ; Satoru Sumitsuji ; MD^a ; Shunsuke Saito ; MD^c ; Taichi Sakaguchi ; MD^c ; Norihide Fukushima ; MD^c ; Shinsuke Nanto ; MD ; FJCC^a ; Yoshiki Sawa ; MD ; FJCC^c ; Issei Komuro ; MD ; FJCC^a
• 关键词：Everolimus ; Cardiac allograft vasculopathy ; Plaque regression ; Heart transplantation ; Intravascular ultrasound
• 刊名：Journal of Cardiology Cases
• 出版年：2013
• 出版时间：June, 2013
• 年：2013
• 卷：7
• 期：6
• 页码：e155-e157
• 全文大小：835 K

文摘

A 45-year-old male who had suffered from refractory non-ischemic heart failure treated with a left ventricular assist device received heart transplantation in February 2008. He underwent coronary angiography (CAG) and intravascular ultrasound (IVUS) at 3 months, and 1, 2, and 3 years after surgery. At 3 months, neither significant stenosis on CAG nor plaque on 3 coronary arteries, as assessed by IVUS were observed. However, focal eccentric plaque on proximal left anterior descending artery has developed up to 2 years, despite the fact that risk factors for cardiac allograft vasculopathy were well controlled. At 2 years, everolimus 2.5 mg/day was added to the patient's existing regimen consisting of corticosteroids, mycophenolate mofetil, and cyclosporine. Then mycophenolate mofetil was withdrawn. At 3 years, concomitant with plaque regression, a decreased plaque volume index, enlarged lumen volume index, and increased minimum lumen area were observed. We experienced a case with plaque regression associated with everolimus administration. Further investigations are needed to explore the mechanism of plaque regression associated with everolimus, as well as to confirm our observation in randomized controlled trials for patients after heart transplantation.

<Learning objective: We experienced a case with plaque regression associated with everolimus administration. Further investigations are needed to explore the mechanism of plaque regression associated with everolimus, as well as to confirm our observation in randomized controlled trials for patients after heart transplantation.>